Patients with RET gene mutations were identified in 12 out of 605 (1.98%) ovarian cancer patients (Additional file 2: Supplementary Table 2), and those with RET alterations had shorter progression-free survival than those without RET alterations (11.27 versus 18.13 months; Fig. 1c), which indicated that RET alterations play a role in the progression of ovarian cancer. This evidence concerns the gene RET and ovarian carcinoma.